Please login to the form below

Stem Cell Therapeutics

This page shows the latest Stem Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies. There is a new player on the stem cell therapy stage, thanks to $225m in start-up funding from Bayer ... BlueRock's founding and scientific investigation team

Latest news

Orphan status for Stem Cell's leukaemia drug

Tigecycline wins FDA rare disease designation. US regulators have granted orphan drug status to tigecycline, a cancer drug in development by Stem Cell Therapeutics. ... Tigecycline is being investigated by Stem Cell Therapeutics for its use in the
UK regenerative medicine projects get £8.5m boost

Novel stem cell manufacturing technologies. • Cell labelling and tracking technologies for quality control and monitoring in the body. • ... Regenerative medicine is an interdisciplinary approach that spans tissue engineering, developmental and stem
Survival strategy

Licenser/Partner. Product/Technology. Development status. Headline ($m). Mesoblast/Cephalon. Stem cell therapeutics in CHF. ... Immunotherapy company acquisition. . 428. Theramex/Teva. Branded product company acquisition. . 368. Evotec/MedImmune.
Diabetes favoured

and Oncomed's $428m strategic alliance with Bayer Schering Pharma (BSP) to discover, develop and commercialise novel anti-cancer stem cell therapeutics. ... Anti-cancer stem cell therapy platform. Discovery. 428. Ascenta Therapeutics/sanofi-aventis.
Indian stem cell companies seek UK links

Leading Indian stem cell companies are in the UK this week to seek ways to build links with the UK stem cell sector. ... Without UKTI's help, we would have had to spend a huge amount of time and expense trying to obtain all the required information on

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Deal Watch table for October 2013

Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast . ... Asset acquisition. Mesenchymal stem cell business, including Prochymal (approved). 100. †Hutchison MediPharma / Eli Lilly.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....